Document is current
Any future updates will be listed below
-
Authors
Cox, Andrea L.
El-Sayed, Manal H. https://orcid.org/0000-0002-6613-0276
Kao, Jia-Horng https://orcid.org/0000-0002-2442-7952
Lazarus, Jeffrey V. https://orcid.org/0000-0001-9618-2299
Lemoine, Maud
Lok, Anna S.
Zoulim, Fabien https://orcid.org/0000-0002-2245-0083
- License Information
-
More Information
Article History
Accepted: 9 June 2020
First Online: 23 July 2020
Competing interests
: M.H.E.-S. has received an educational grant from Gilead. J.-H.K. declares that he has acted as a consultant for Arbutus, Gilead Sciences and Roche, and appeared on speaker’s bureau for Bristol-Myers Squibb, Gilead Sciences, Fujirebio, Merck Sharp & Dohme and Roche. J.V.L. reports grants and personal fees from AbbVie, Gilead Sciences and MSD, and personal fees from CEPHEID, GlaxoSmithKline, Intercept and Janssen, outside of the submitted work. M.L. has received funding and fees from Gilead and Viiv Health care. A.S.L. acknowledges research grants (to the University) from Assembly, Bristol-Myers Squibb, Gilead, and TARGET, and has served on advisory boards or as a consultant for Gilead, GlaxoSmithKline, Huahui, Spring Bank and TARGET. F.Z. has research contracts through INSERM with Evotec and Roche. He has also acted as an advisor or consultant for Assembly, Aligos, Evotec, Galapagos, Gilead, GlaxoSmithKline, Myr Pharma, Roche Molecular Systems, Transgene and Vir Bio. A.L.C. declares no competing interests.
